Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Sarcoma 3Rectal Neoplasms 3Colonic Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Melanoma 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Skin Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasms, Unknown Primary 1Nasopharyngeal Neoplasms 1Mesothelioma, Malignant 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 13fludarabine phosphate 8Etoposide 8Methotrexate 7Idarubicin 6Daunorubicin 6Busulfan 6tipifarnib 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5Vorinostat 4Tacrolimus 4Mitoxantrone 4Cyclophosphamide 4Azacitidine 4Antilymphocyte Serum 4merphos 3Topotecan 3Thioguanine 3Cyclosporine 3sargramostim 2laromustine 2Specimen Handling 2Radiotherapy 2Methylprednisolone 2Lenalidomide 2Hydrocortisone 2Granulocyte-Macrophage Colony-Stimulating Factor 2Dexamethasone 2Decitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Anemia, Refractory, with Excess of Blasts × Semaxinib × Clear all
NCT00005942 2013-01-23

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

National Cancer Institute (NCI)

Phase 1/2 Completed
37 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡